Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
29 September 2023 - 1:30PM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief
Scientific Officer, Head of Research, Development and Medical, will
be among the featured speakers at the 4th Annual Gene Therapy for
Ophthalmic Disorders conference, which is being held October 3-5,
2023 in Boston, Mass.
Dr. Upadhyay will be speaking during two sessions:
WorkshopTopic: Endpoints for Gene
Therapy Clinical Trials in OphthalmologyDate:
October 3, 2023 Time: 9 a.m. - noon ET
Presentation Session:
Fine-tuning the Design of First-in-Human Clinical
StudiesTopic: Striking a Balance with Ascending
Dose StudiesDate: October 5,
2023Time: 11:20 - 11:50 a.m. ET
About Ocugen, Inc. Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patients’ lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on Twitter and LinkedIn.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations. These and other risks and uncertainties
are more fully described in our periodic filings with the
Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact: Tiffany Hamilton Head of
Communications Tiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024